Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interferon alfa + JAK1/2 inhibitor (Jakavi) in Philadelphia chromosome–negative chronic myeloid neoplasms
2013-003295-12Phase 2Completed
- Sponsor
- Zealand University Hospital, Roskilde
- Start
- Oct 2013
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, single-arm trial of ruxolitinib and peginterferon alfa-2a in myelofibrosis (MF) and chronic myelogenous leukemia (CML), sponsored by Zealand University Hospital, Roskilde. Started Oct 2013; status: completed.
02
Drugs
ruxolitinibpeginterferon alfa-2a
03
Conditions
myelofibrosis (MF)chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2013-003295-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003295-12.